Alain Tedgui obtained his PhD in Fluid Mechanics, then worked on the mechanisms of macromolecule transport in the arterial wall that play a major role in atherogenesis, in the Physiological Flow Studies Unit at the Imperial College, London. After his post-doctoral fellowship he joined the French Institute of Health and Medical Research (INSERM) in 1983. He headed an INSERM laboratory at the Paris Hospital Lariboisière from 2000 to 2004.
His current primary research is aimed at elucidating the role of apoptosis and inflammation in atherosclerosis. His group has shown that apoptotic death leading to the generation of apoptotic microparticles is the major determinant of the thrombogenicity of the lipid core. More recently, he bridged the interface between vascular biology and immunology in showing that a subset of immune cells, CD4+CD25+ regulatory T cells, limits the development of atherosclerosis and can be used as a promising anti-atherosclerotic strategy to curtail inflammation. He is the European Editor of Arteriosclerosi Thrombosis and Vascular Biology.